Limitations in current insulin formulations contribute to suboptimal glycemic control and increased risks of hypoglycemia and hyperglycemia. Afrezza® with Technosphere® inhaled insulin (TI) offers a novel therapeutic option with a rapid pharmacokinetic and pharmacodynamic profile, addressing challenges associated with injectable insulin therapies. This article presents case reports that illustrate the clinical applications of TI across diverse patient populations, including type 1 diabetes, type 2 diabetes (T2D), pregnancy complicated by T2D, and exercise-related glycemic management.
SinghA, AfshanN, SinghA, et al.Recent trends and advances in type 1 diabetes therapeutics: A comprehensive review. Eur J Cell Biol, 2023; 102(2):151329; doi: 10.1016/j.ejcb.2023.151329
2.
von ScholtenBJ, KreinerFF, GoughSCL, von HerrathM. Current and future therapies for type 1 diabetes. Diabetologia, 2021; 64(5):1037–1048; doi: 10.1007/s00125-021-05398-3
3.
HeinemannL, BaughmanR, BossA, HompeschM. Pharmacokinetic and pharmacodynamic properties of a novel inhaled insulin. J Diabetes Sci Technol, 2017; 11(1):148–156; doi: 10.1177/1932296816658055
4.
HallerMJ, JonesMC, BhavsarS, KaisermanKB. Time-action profile of technosphere insulin in children with type 1 diabetes. Diabetes Ther, 2023; 14(3):611–617; doi: 10.1007/s13300-023-01368-7
5.
GoudieRJ, LunnD, HovorkaR, MurphyHR. Pharmacokinetics of insulin aspart in pregnant women with type 1 diabetes: Every day is different. Diabetes Care, 2014; 37(6):e121–e122; doi: 10.2337/dc13-2535
